FDA warns telehealth seller GoodGirlRX that its website misbrands compounded semaglutide and tirzepatide, claiming FDA approval and implying it is the compounder.
What happened
FDA reviewed the website goodgirlrx.com in December 2025 and found it offering compounded semaglutide and tirzepatide drug products. The product labels pictured on the site show "GoodGirlRX," which suggests the company compounds the drugs when it does not. The site also carried the claims "FDA-approved meds," "FDA-approved options," and "Clinically proven GLP-1 results," although compounded drugs are not FDA-approved.
What FDA found
The website labels name GoodGirlRX as the maker of compounded drugs it does not make, which is false and misleading labeling.
FDCA section 502(a) [21 U.S.C. § 352(a)]; 21 CFR § 201.1(h)(2)Advertising for a compounded drug is false or misleading when it suggests the company is the compounder.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]The site calls the products "FDA-approved meds" and "FDA-approved options," but compounded drugs are not FDA-approved.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The claim of "clinically proven GLP-1 results" implies the products were evaluated for safety and effectiveness when they were not.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Shipping misbranded drugs across state lines is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells the company to take immediate action and to send the Office of Compounding Quality and Compliance a written response within 15 working days describing the steps taken and how it will prevent repeat violations. The response should name the entities that make the compounded products, include a sample of labeling, and address or show removal of the website claims.
Who should pay attention
- telehealth platforms that market compounded GLP-1 drugs
- compounding pharmacies whose products are resold or relabeled by others
- marketing teams that write website claims for prescription products
This is a summary. Read the original letter on fda.gov.